Valsartan, Losartan & Other BP Med Recalls 2018-19

March 12, 2020 in News by RBN Staff


Source: WebMD

Note: This story was updated on Sept. 23, 2019, with an additional losartan recall from Torrent Pharmaceuticals.  

Dozens of medications used to treat high blood pressure have been recalled over the past several months as federal investigators discover potentially cancer-causing impurities in them. When American Health Packaging recalled one lot of valsartan pills on March 7, the Public Interest Research Group said it was the 75th recall of blood pressure medications since the problem first appeared.

These common prescription drugs include valsartanlosartan, and irbesartan in different combinations and from different manufacturers.

The problems have become so widespread that on March 12 the FDA prioritized approval of a new generic of valsartan to help relieve shortages of the drug. In April, the agency  released a list of 40 blood pressure medications it says are free from contamination. You can find the list here.

“Our goal is for this information to help health care providers as they consider acceptable treatment options for their patients,” the agency said in a statement.


The FDA is also working to determine what exactly has caused the impurities and what changes need to be made in the manufacturing process to prevent it. The Public Interest Research Group said in March that the FDA needs to step up the pace.

“After 75 recalls it is clear more aggressive action is needed,” PIRG consumer watchdog Adam Garber said in a release. “Americans expect their blood pressure medicadtion to treat their conditions, not cause cancer. The FDA needs to finish its investigation and develop a plan to prevent further contamination.”

Almost 60 million prescriptions were written for losartan drugs in 2016 and 14 million for valsartan or a drug that includes it. An additional 3.6 million prescriptions were written for irbesartan that year. Here’s what you need to know.

What blood pressure drugs have been recalled?

Valsartan. There have been so many types of valsartan recalled this year that the FDA has created a website listing just for them. The latest is American Health Packaging’s 160 mg valsartan tablets, lot number 179791 that expire on March 31, 2020. The pills come in 100-count blister packs with NDC number 60687-139-01.

The agency has also created a page that lists the drugs that have not been recalled.

Losartan. In December, the FDA announced a voluntary recall of losartan potassium tablets USP.  An addition eight lots of Torrent Pharmaceuticals’ losartan tablets were added to a previous recall in January. See which products were affected by the recall.

In November, the FDA announced a voluntary recall of losartan potassium/hydrochlorothiazide, 100 mg/25 mg tablets in 1,000-count plastic bottles, NDC 0781-5207-10, Lot number JB8912, Exp. Date 06/2020.

Torrent’s recall was expanded on Jan. 22 to include 10 additional lots of losartan potassium tablets, and six lots of losartan potassium and hydrochlorothiazide tablets. Torrent further expanded the recall in April for 36 more lots of losartan potassium tablets and 68 lots of losartan potassium/hydrochlorothiazide tablets. In September, Torrent announced that an additional three lots of losartan potassium tablets in 100 mg and 50 mg doses, and two lots of losartan potassium/hydrochlorothiazide tablets 50 mg/12.5 mg, and 100 mg/25 mg are being recalled as well. See the full list here.

Macleods Pharmaceuticals Limited on Feb. 25 recalled one lot of losartan potassium/hydrochlorothiazide combination tablets 100mg/25mg, with a July 2019 expiration date. Macleods on June 26 also recalled 32 lots of losartan potassium including two lots of 50 mg tablets and losartan potassium/hydrochlorothiazide tablets, including 12 lots of 50 mg/12.5 mg strength, three lots of 100 mg/12.5 mg and 15 lots of 100 mg/25 mg strength.

Camber Pharmaceuticals on Feb. 28 recalled 87 lots of losartan tablets USP 25mg, 50 mg and 100 mg. See the affected products and what the label looks like.

Legacy Pharmaceutical Packaging, LLC on March 15 recalled 43 lots of losartan tablets. On April 24, the company recalled an additional lot of 50mg losartan tablets. See a list of affected products here and here.

Teva Pharmaceuticals USA on April 26 recalled 35 lots of losartan potassium tablets (6 lots of 25 mg pills and 29 lots of 100 mg) that were sold exclusively to the Golden State Medical Supply of Camarillo, CA. Golden State re-packages the tablets under its own label for retail sale. Teva expanded this recall on June 10, 2019, with another six lots of losartan potassium USP tablets in 50mg and 100mg strength.  See all the affected products here.

On May 4, Vivimed Life Sciences Pvt Ltd recalled 19 lots of losartan potassium tablets in 25 mg, 50 mg and 100 mg doses. The drugs were made in India and distributed by Heritage Pharmaceuticals of East Brunswick, NJ. For details on the recalled drugs, visit the FDA’s website.

Irbesartan. In July, the FDA announced a voluntary recall of irbesartan tablets. See which products were affected by the recall.  In January 2019, Prinston Pharmaceutical Inc., doing business as Solco Healthcare LLC, voluntarily recalled eight llots of irbersartan-based drugs. These are not yet listed on the FDA’s website of all recalled ibersartan products. The recall involves irbersartan and irbersartan HCTZ tabletes manufactured in China.

Why are the drugs being recalled?

In each case, a recalled drug was contaminated with N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) or N-Nitroso N-Methyl 4-amino butyric acid (NMBA).

Thosechemicals are believed to cause cancer in humans. Research also suggests NDEA can cause liver and blood cell damage.

NDEA is used to make rocket fuel and can also be found in some food and drinking water, but at low levels. It can also be a created through certain chemical reactions and as a byproduct of industrial processes.

What is the risk of getting cancer from one of these drugs?

The FDA says it is very small. The amount of NDMA found in the recalled valsartan drugs exceeds acceptable levels. Records from drug manufacturers show the impurity may have been in the valsartan products for up to 4 years. The FDA estimates that if 8,000 people took the highest valsartan dose, which is 320 milligrams, from recalled batches every day for 4 years, there would likely only be one additional case of cancer over the life of those 8,000 people.

For context, 1 in 3 people in the United States will be diagnosed with cancer in their lifetime.

What’s driving the spike in recalls?

A common thread among all of these recalls is that the drugs, or ingredients in the drugs, were all made in China or India.

American drug companies since the 1990s have increasingly used factories in other countries to manufacture their products. About 40% of finished medications are made overseas, the Government Accountability Office says. Nearly 8 out of 10 active pharmaceutical ingredients, which are made into pills at other plants, are, too.

This globalization of the nation’s drug supply helps keep prices down, as it is cheaper to have them made in other countries. But with lower costs sometimes comes lower quality control.

What’s being done about products made in other countries?

An FDA spokesman says the agency is still investigating how these drugs became contaminated. Inspectors believe contaminated compounds were unintentionally created through a chemical reaction.

What should people who rely on these medicines do?

Experts say anyone taking a recalled drug should continue to do so, but contact your doctor or pharmacist immediately. The threat from the contamination may be less than the threat of not taking the drug.

Your doctor or pharmacist can help you find an alternative. But at least one expert says the recalls are making it more difficult to find valsartan drugs that have not been recalled. And, he says, some blood pressure drugs not on the recall list have seen price increases as demand spikes.

WebMD Medical Reference Reviewed by Michael W. Smith, MD on December 11, 2018


Article: Valsartan, Losartan and Other Blood Pressure Medication Recalls 2018-19

Craig Beavers, PharmD, cardiovascular clinical pharmacy coordinator, University of Kentucky Medical Center. “Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the agency’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue;” “Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API),” “Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API),” “FDA approves a new generic valsartan,” “UPDATED:ADDITIONAL LOTS ADDED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets,” “FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products,” “Analysis of N-nitrosodimethylamine (NDMA) Levels in Recalled Valsartan in the U.S.,” “FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan,” “Irbesartan products under recall – Updated October 29, 2018,” “Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API),” “Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API),” “Valsartan products not currently recalled – Updated December 4, 2018,” “Valsartan products under recall – Updated December 4, 2018.”

FDA spokesman Jeremy Kahn.

Robert Handfield, director of Supply Chain Resource Cooperative, North Carolina State University.

Atlanta Journal-Constitution: “Blood pressure medication recalls: Everything you should know, Atlanta doctors, experts say.” “Valsartan Drug Usage Statistics, United States, 2006 – 2016.”

Public Interest Research Group: “Blood pressure medication recalled for 75th time in 8 months.”

Slideshow: Slideshow: A Visual Guide to High Blood Pressure


1), Photo Researchers
2)     Laura Doss/Fancy
3)     Jutta Klee/Ableimages
4)     Comstock
5)     Deborah Davis/Photonica
6)     Tiziou/Photononstop
7)     Andersen Ross/Blend Images
8)     Amana Productions
9)     Joanne Obrien/Photolibrary
10)   Nisian Hughes/Lifesize
11)   Isabelle Rozenbaum/PhotoAlto
12)   Wesley Hitt/Tips Italia
13)   Erik Isakson/Blend Images
14)   Pixtal Images
15)   Martin Barraud/OJO Images
16)   Image Source
17)   Jupiterimages/FoodPix
18)   Ariel Skelly/Blend Images
19)   iStock, Top Photo
20)  Science Picture Co.
21)  Steve Oh, M.S. / Phototake
22)  Huntstock
23)  Val Loh/Photonica
24)  Tom Grill/Iconica
25)  Stewart Cohen/The Image Bank
26)  Foodcollection


American Heart Association:  “Stroke,” “Understanding Blood Pressure Readings,” “What Are the Symptoms of High Blood Pressure?” “Hypertensive Crisis,” “Understand Your Risk for High Blood Pressure,” “High Blood Pressure and African Americans,” “Shaking the Salt Habit,” “Caffeine and Blood Pressure,” “Over-the-Counter Medications,” “High Blood Pressure in Children,” “Types of Blood Pressure Medications.”

CDC: “High Blood Pressure Facts,” “About High Blood Pressure,” “Physical Activity and Health.”

FDA: “Medications for High Blood Pressure.”

National Heart, Lung, and Blood Institute, National Institutes of Health: “What is High Blood Pressure?” “What are High Blood Pressure and Prehypertension?” “Your Guide to Lowering Your Blood Pressure with DASH,” “Living with High Blood Pressure,” “What is Preeclampsia?” “High Blood Pressure Detection,” “How is High Blood Pressure Treated?”

The American College of Obstetricians and Gynecologists: “High Blood Pressure During Pregnancy.”

The Harvard Medical School Family Health Guide: “Prehypertension: Does it really matter?”

U.S. Department of Health and Human Services: “Your Guide to Lowering Blood Pressure.”

Verdecchia, P. European Heart Journal, 2002

© 2018 WebMD, LLC. All rights reserved.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: